GMR Hyderabad Air Cargo (GHAC), a 100 per cent subsidiary of GMR Hyderabad International Airport Ltd (GHIAL), on Tuesday said that it is ready to handle export and import of Covid-19 vaccines.
Hyderabad is likely to emerge as a major port once the key manufacturers succeed with the ongoing human trials.
GHAC is in talks with various stakeholders towards meeting specific requirements of export and import of Covid-19 vaccines, including the challenge of having multiple range of cold and ultra-cold minus temperatures.
It has a major role cut out in the entire value chain of vaccine shipments to provide the necessary infrastructure for unbroken cool-chain for the global vaccine shipments to maintain the vaccine integrity.
Experts say that Hyderabad, the pharma hub and vaccine capital of India, will be an integral part of the Covid-19 solution by virtue of its robust manufacturing technology and capacity to manufacture millions of doses as per the best in class industry practices.
As per the industry insights, most of India's vaccine export will be to Africa, Latin America and Asian destinations. Ingredients may be obtained from Europe and few other regions.
The Covid-19 vaccines require specialised handling, hence the procedures are being developed in coordination with manufacturers and supply-chain players to mitigate any risk during the process of transportation of vaccines right from the manufacturers' facility to the final destination.
GHAC has well-established standard operating procedures (SOP) in place for acceptance, screening and handling of vaccines as per required temperature conditions. The pharma zone of the terminal is a WHO-GSDP (World Health Organization - Good Storage and Distribution Practices) certified facility. It provides end-to-end unbroken cool-chain for pharmaceutical and vaccine shipments.
09/12/20 IANS/News18.com
To Read the News in full at Source, Click the Headline
0 comments:
Post a Comment